BioPlex 2200 ANA Screen with MDSS
Streamline your ANA testing workflow, deliver results faster, and provide better patient care. Our fully automated multiplex assay allows ANA screen and individual antibody results to be reported as needed from a single test.
BioPlex 2200 ANA Screen with MDSS
This multiplex test panel detects and differentiates clinically relevant antinuclear antibodies used to aid in diagnosing connective tissue diseases (CTDs). The MDSS Software may be used to associate positive ANA result profiles with specific CTDs.
* SS-A (52 and 60) is reported as a composite result in the U.S.
† RNP (A and 68) is reported as a composite result in the U.S.
‡ ANA Screen is a composite roll up of all individual results.
- Pérez D et al. (2018). Predictive autoimmunity using autoantibodies: screening for anti-nuclear antibodies. Clin Chem Lab Med 56(10), 1771–1777.
- Retzlaff K (2018). New study reveals limitations in ANA test kits for lupus. https://www.the-rheumatologist.org/article/new-study-reveals-limitations-in-ana-test-kits-for-lupus/, accessed July 3, 2024.
- Snyder MR (2019). A basic guide to ANA testing. https://www.aacc.org/cln/articles/2019/april/a-basic-guide-to-antinuclear-antibody-ana-testing, accessed July 3, 2024.
- Albert C (2020). Addressing the shortcomings of ANA testing by IFA. https://www.captodayonline.com/addressing-the-shortcomings-of-ana-testing-by-ifa/, accessed July 3, 2024.
- Deng X et al. (2016). Utility of antinuclear antibody screening by various methods in a clinical laboratory patient cohort. J Appl Lab Med 1, 36-46.
Improve Patient Care
Patient care is at the heart of what you do. From faster turnaround times to high-quality, clinically relevant results, we’ll help you help your patients.
Faster Result Turnaround Time
The BioPlex 2200 ANA Screen uses multiplex technology to provide multiple results per test and accelerate result turnaround time of ANA screening and follow-up testing. This may enable faster diagnoses and improve patient outcomes.
Reliable Results with Quality Control in Every Test
Quality control beads unique to the BioPlex 2200 System are integrated into every test, enabling real-time analysis of assay parameters. This ensures confidence in every result.
Clinically Relevant Results
"We can conclude that the BioPlex ANA Screen has more sensitivity than the IIF on HEp-2 cells for the detection of autoantibodies that are clinically relevant, as it can detect “pathological” antibodies at least 3 years before IIF.”
Pérez D et al. (2018)1
For initial ANA testing, many clinicians utilize traditional HEp-2 IFA. However, there is ongoing debate about clinical performance limitations of IFA testing for ANA.2–4 IFA alone does not provide the specific autoantibody results that contribute to disease diagnosis.
The BioPlex 2200 ANA Screen can add up to 13 individual, clinically relevant results* (up to 11 results in the U.S.) to enhance diagnostic accuracy. While the test can be used to complement IFA, comparative studies have shown that the BioPlex 2200 ANA Screen alone offers similar or superior clinical performance.5
Autoantibody Testing: Is There Still a Gold Standard?
This article provides tips to help your lab maintain ANA screening in house after HEp-2 IFA expertise is lost.
Simplified Result Interpretation
- Systemic lupus erythematosus (SLE)
- Mixed connective tissue disease (MCTD)
- Sjögren’s syndrome (SS)
- Scleroderma (systemic sclerosis
- Polymyositis
The BioPlex 2200 Medical Decision Support Software (MDSS) is an optional feature that allows your lab to simplify interpretation of ANA screen assay results. MDSS uses an interpretive software algorithm that associates patient antibody results with the following connective tissues diseases:
Reduce Costs
By generating more results with less operator effort, your lab can minimize staffing and test processing costs. By reporting both an ANA screen composite result and individual autoantibody results from a single in-house test, you can avoid send-out testing costs.
Staffing costs
Multiplexing helps lighten staff workloads, reduce hands-on time, and free technicians to focus on other value-added activities.
Test processing costs
Replacing individual autoantibody tests with a single multiplex ANA screen panel means fewer tests, fewer calibrations, fewer quality control runs, and fewer reagents and consumable supplies.
ANA send-out testing costs
Performing ANA screening and follow-up testing in house helps minimize expenses and inefficiencies associated with send-out testing. *
Case Study: Monthly Labor Time Comparison
See how you can minimize labor costs and make optimal use of medical laboratory technologists — your lab’s most valuable resource.
This case study compares manual processing time of the BioPlex 2200 ANA Screen to a competing automated ANA EIA system. Data are based on an actual lab’s monthly ANA screen volume with a 20% follow-up rate.
In total, 63% less hands-on time was required with multiplexing than with the competing automated ANA EIAs.
For a personalized workflow analysis of your lab, please contact your Bio-Rad representatives.
Maximize Efficiency and Minimize Effort
Your lab can boost productivity and improve management of ANA workloads. Enhance throughput, reduce hands-on time, streamline ANA testing operations, and much more.
Get More Results per Test
Through the power of multiplexing, your lab can provide multiple ANA results from a single test. This enables far higher throughput than with traditional EIA or IFA methods.
Enhance Throughput
By processing 100 samples per hour on the fully automated BioPlex 2200 System, your laboratory can deliver up to 1,400 autoimmune results per hour.
Enhance Throughput
By processing 100 samples per hour on the fully automated BioPlex 2200 System, your laboratory can deliver up to 1,200 autoimmune results per hour.
Increase Walkaway Time
Traditional ANA tests may require numerous manual processing steps. But with full automation and multiplex technology, the BioPlex 2200 System allows technicians to complete their ANA testing workload with less hands-on time. Simply load the samples and walk away.
Simplify Management of ANA Testing Algorithms
Regardless of the methods you currently use for ANA screening and follow-up testing, the BioPlex 2200 ANA Screen can help you streamline testing and save significant time and labor.
With the multiplexing add-on feature of the BioPlex 2200 System software, additional results can be added individually following a positive ANA screen result. Up to 13 separate analyte results can be reported immediately as needed.
A Better Way to Manage Antinuclear Autoantibody Testing
This article reviews advantages and limitations of ANA screening methods and gives examples on integrating multiplex immunoassays into ANA workflows.
Manage Loss of IFA Expertise
What should laboratories do when medical laboratory scientists with specialized IFA expertise are lost? Send-out testing is not the only option. The fully automated BioPlex 2200 ANA Screen simplifies screening and follow-up testing. Your lab can maintain ANA screening in house without requiring specialized IFA expertise.
Antinuclear Antibody Testing: How to Manage Loss of HEp-2 IFA Expertise
This article provides tips to help your lab maintain ANA screening in house after HEp-2 IFA expertise is lost.
A Better Way for ANA
Antinuclear antibody (ANA) screening has traditionally been performed using the HEp-2 immunofluorescence assay (IFA) method followed by individual autoantibody tests using solid-phase methods. Today, laboratories that perform ANA screening face pressure to improve turnaround time, boost result throughput, and accomplish more with fewer resources.
Discover a better way to manage your ANA testing algorithms, made possible by multiplex technology. Unlike traditional solid-phase methods, which measure only one analyte at a time, the BioPlex 2200 ANA Screen provides up to 14 individual results per test: a composite ANA screen result plus up to 13 ANA analyte results.
This test can be used as an aid in the diagnosis of systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), Sjögren’s syndrome (SS), scleroderma (systemic sclerosis), and polymyositis.
Each BioPlex 2200 ANA Screen test delivers up to 14 individual results
- ANA screen result‡
- Ribosomal protein
- SS-B
- RNP A†
- Centromere B
- dsDNA (quantitative)
- SS-A 52*
- Sm
- RNP 68†
- Jo-1
- Chromatin
- SS-A 60*
- Sm/RNP
- Scl-70